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Abstract 
Two human IFN-β expression systems were derived based on the pIRES2-AcGFP1 
plasmid backbone. One expression plasmid encoded human IFN-β fused to a C-terminal linker 
and an 8-histidine affinity chromatography tag. A second expression plasmid encoded human 
IFN-β without the C-terminal additions to determine if the addition of the 8-his tag alters IFN-β 
function. Both expression vectors encoded the native signal sequence to direct secretion of IFN-β 
as a glycosylated soluble protein. These plasmids were then transfected into Chinese Hamster 
Ovary (CHO) cells. Stable transfected CHO cells were selected based on plasmid-encoded 
resistance to the antibiotic Geneticin. IFN-β-producing cells were selected by Fluorescence-
Activated Cell Sorting of the brightest 10% fraction of GFP+ cells. Expression supernatants from 
each cell line exhibited similar amounts of cytotoxic activity in the IFN-β reactive TF-1 
erythroleukemia cell line. These results provided suggestive evidence that the C-terminal affinity 
tag did not adversely affect the activity of the N-terminal IFN-β cytokine domain. This IFN-β-
8his recombinant protein was purified by Ni-NTA affinity chromatography and was shown to 
exhibit potent activity in the in vitro TF-1 cytotoxicity assay. Human peripheral blood 
mononuclear cells (PBMCs) were activated with Con-A, IL-2, and either IFN-β, TGF-β, IFN-β + 
TGF-β, or no additional cytokine. Cell numbers were counted at each passage. The main finding 
was that IFN-β caused the induction of T cell anergy.  Human T cells (90% CD8+) were 
activated with RS4 (11) cells (acute lymphoblastic leukemia cell line), Con-A, and IL-2 in the 
presence or absence of IFN-β, TGF-β, IFN-β + TGF-β. T cells were cultured for eight days, and 
then reactivated. Supernatants were collected from reactivation cultures to measure IL-2 
production as a measure of T cell responsiveness. Human T cells activated in the presence of 
IFN-β and TGF-β produced less IL-2 compared to T cells activated in the presence of TGF-β 
alone.  This expression system will be used to reveal whether IFN-β elicits differentiation of 
human FOXP3+ Tregs. 
Introduction 
Multiple Sclerosis (MS) is an inflammatory, demyelinating autoimmune disorder of the 
central nervous system (CNS) that afflicts more than 2 million people globally (1). MS is a 
prominent cause of neurological disability in young adult populations (2). MS is characterized by 
a loss of either sensory or motor function due to permanent axonal damage (2). MS is 
demonstrated clinically through a variety of nervous system complications. The common 
presentations of MS include optic neuritis, cognitive impairment, partial transverse myelitis, or 
diplopia (3). Cerebral hemisphere lesions are also presented with symptoms including aphasia 
and encephalopathy (3). Most frequently, individuals with MS experience periods of relapsing 
symptoms followed by periods of remission, which is termed relapsing-remitting multiple 
sclerosis (1). Despite the prevalence of MS, the underlying mechanism causing the disease 
remains unknown. Current evidence suggests peripheral Th1 and Th17 cells are activated and 
migrate into the CNS by inducing a proinflammatory response via cytokine production (4). Due 
to molecular mimicry, myelin reactive T cells are reactivated in the CNS to release inflammatory 
cytokines and chemokines, permitting migration of CD8+ T cells and neutrophils into the CNS 
(4). As a result, the myelin sheath is damaged by the inflammatory response (4).  
Currently there is no cure for MS, though IFN-β has historically been used as the primary 
FDA-approved treatment for the disease. Recombinant IFN-β produced in E. coli was the first 
approved form of MS treatment in 1993 (5). By 1996, recombinant IFN-β drugs were produced 
by use of CHO cells to express IFN-β (5). These medications demonstrated a reduced rate of 
annual relapse of MS presentation (5). IFN-β also elicits a reduction in brain lesion formation as 
observed in clinical trials (5). Evidence suggests IFN-β has the capability to lessen the severity of 
MS presentation, though the mechanism of IFN-β function in the body is not fully understood. It 
is proposed that IFN-β increases anti-inflammatory cytokine production such as IL-10 and IL-4 
(6). IFN-β is also suggested to decrease the production of proinflammatory cytokines such as IL-
17 and osteopontin (6). There is no substantial evidence currently to affirm how IFN-β is able to 
increase or decrease specific cytokine production. 
Recent research regarding IFN-β has focused on T regulatory (Treg) cells. Tregs are a 
subclass of T cells that are derived from naïve T cells in the thymus or the periphery (7). Tregs 
suppress effector T cells, inhibiting autoimmune responses from occurring in the body (7). 
CD4+CD25+ Treg development and function are regulated by the transcription factor Foxp3 (7). 
Foxp3 is crucial for T cell differentiation into Tregs, and high levels of Foxp3 is necessary for 
immunological suppression of effector T cells by Tregs (7). Past studies have demonstrated how 
TGF-β is required for T cell differentiation during immune responses, including the upregulation 
of Tregs (8). However, in regards to IFN-β, recent preclinical studies in mouse models of MS 
showed that IFN-β elicits an immunosuppressive subset of FOXP3+ Tregs, which in turn 
suppress CNS demyelinating disease in mice (9). Given that mouse IFN-β elicits Tregs in mice, a 
central question is whether human IFN-β elicits differentiation of human FOXP3+ Tregs in 
primary T cell cultures. The purpose of this project is to derive new mammalian IFN-β 
expression systems to support studies assessing whether human IFN-β elicits or stabilizes human 
Tregs.   
 
Materials and Methods 
Preparation of IFN-β and IFN-β-8his plasmids 
Human IFN-β untagged clone plasmid was obtained from Origene. After reconstitution, 
the IFN-β plasmid was transformed into Top 10 E. coli by use of electroporation. An initial 
screen was performed via PCR to identify bacterial colonies with the IFN-β plasmid. The IFN-β 
plasmid from positive E. coli was amplified and prepared for the extension PCR reaction by PCR 
with forward and reverse primers. A different reverse primer was used to encode an 8-histidine 
tag at the C terminal end of the IFN-β gene on a select number of IFN-β plasmids, generating 
two different IFN-β plasmids. 
Generation of pIRES2-AcGFP1 with IFN-β or IFN-β-8his 
Previously prepared Top 10 E. coli containing the pIRES2-AcGFP1 (Clontech) plasmid 
were cultured on Luria Broth (LB) with kanamycin. pIRES2-AcGFP1 was isolated from the Top 
10 E. coli and amplified. The IFN-β or IFN-β-8his PCR product was inserted into the pIRES2-
AcGFP1 by an extension PCR reaction using 5 ul of the previous PCR product and 2 ug of 
pIRES2-AcGFP1. Extension PCR reaction products were digested with restriction endonucleases 
(SmaI, SalI-HF, EcoRI-HF, Eco53KI, AfeI, DpnI) to isolate the newly formed pIRES2-AcGFP1 
IFN-β-8his plasmid. The pIRES2-AcGFP1 IFN-β and pIRES2-AcGFP1 IFN-β-8his plasmids 
were transformed into Top 10 E. coli. PCR screening of the Top 10 E. coli was conducted to 
verify the creation of the plasmids. 
 
Transfection of pIRES2-AcGFP1 IFN-β and pIRES2-AcGFP1 IFN-β-8his into 
CHO Cells 
CHO cells cultures were established and used for pIRES2-AcGFP1 transfection. 5 ug of 
either pIRES2-AcGFP1 IFN-β or pIRES2-AcGFP1 IFN-β-8his were prepared in serum free 
DMEM and Turbofect Transfection Reagent (ThermoFisher) before being added dropwise to 
CHO cell cultures in complete DMEM (CDMEM). Expression of Green Fluorescent Protein 
(GFP) by the CHO cells was examined by flow cytometry, indicating successful transfection. 
CHO cells were cultured in CDMEM with Geneticin (G418). The brightest fraction of GFP-
expressing CHO cells were separated by flow cytometric sorting. 
Purification of IFN-β-8his  
Supernatant from culture media was periodically collected from the CHO cells that were 
stably transfected with the pIRES2-AcGFP1 IFN-β-8his plasmid. IFN-β-8his expressed in the 
CHO supernatant was purified on Ni-NTA affinity columns. Protein was collected by use of 
wash buffer with varying concentrations of imidazole. Protein electrophoresis was performed on 
the samples of wash buffer containing protein supernatant to determine which elution fractions 
contained the purified IFN-β-8his. The purified IFN-β-8his was concentrated by use of Amicon 





Purified Human IFN-β Cytotoxicity Assay 
To determine whether IFN-β was successfully produced by the pIRES2-AcGFP1 IFN-β 
expression system, TF-1 cells were cultured with the purified IFN-β-8his collected by Ni-NTA 
affinity chromatography. IFN-β has a cytotoxic effect on TF-1 cells, allowing decreased counts 
per minute of cells do be indicative of IFN-β presence. After 3 days, IFN-β concentrations from 
3.2 nM to 0.032 nM produced significantly less TF-1 cells (Figure 1). Results for the purified 
IFN-β-8his were comparable to an IFN-β stock previously purchased, indicating function of the 
IFN-β-8his was not altered by the 8 histidine tag attached. Based on the cytotoxicity present by 
the TF-1 cells, the Origene human IFN-β plasmid was successfully incorporated in the pIRES2-
AcGFP1 plasmid and transformed into CHO cells. 
 















Figure 1. Purified human IFN-β-8his cytotoxicity assay.  On day 0, 10,000 TF-1 cells were 
cultured with designated concentrations of IFN-β or IFN-β-8his. 2 ng/mL GMCSF were added 
per well to stimulate cell growth in all wells.  On day 2, the plate was pulsed with 1 μCi/well 
[3H] thymidine.  On day 3, the plate was harvested and counts per minute (CPM) were analyzed. 
** indicates P<0.001. * indicates P<0.05.   
Induction of T Cell Anergy by IFN-β 
In a preliminary study to investigate the ability of IFN-β to create a T regulatory cell line 
required for MS studies, PBMCs were isolated from patient blood samples and activated for 3 
days with IFN-β and/or TGF-β. The cells were then washed and propagated in IL-2 without IFN-
β or TGF-β. The growth rate was determined on days 3, 6, 11, and 14. On day 6, the prior 
exposure to TGF-β had no effect on the fold change in growth relative to the cell population that 
was activated without cytokine (Figure 2). In contrast, PBMC populations that were activated in 
the presence of IFN-β had a relative decrease in growth compared to control populations. This 
decrement in growth was also observed in the PBMC population activated with both IFN-β and 
TGF-β. The data present provided suggestive evidence that IFN-β dampens mitogenic T cell 
responses, in a primary T cell activation, by inducing T cell anergy. 
 
Figure 2. IFN-β induced T cell anergy.  On day 0, human PBMCs were isolated from whole 
blood by use of a density centrifugation gradient protocol.  PBMCs were activated for 3 days in 
presence of 2.5 μg/mL Con-A, 1% IL-2, and either 10 nM TGF-β, IFN-β, TGF-β + IFN-β, or no 
cytokine.  Cells were counted and passaged every three to five days in fresh media and 1% IL-2 
(without IFN-β and/ or TGF-β). Fold change in growth was determined relative to the previous 
passage.  
IFN-β Induced Inhibition of IL-2 Production by Human T Cells 
In order to evaluate the ability of IFN-β to inhibit T cell proliferation, a T cell line 
comprised of 90% CD8+ human T cells was activated with either IFN-β and/or TGF-β with 
irradiated RS4 (11) cells and IL-2. Once removed from activation media, the cells were cultured 
for seven days in IL-2 in the absence of IFN-β and/ or TGF-β. The cell populations were then 
reactivated in a recall assay (without additional IL-2) to measure mitogen-stimulated IL-2 
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production. Supernatants from these cultures were used to culture SJL-PLP T cells, mouse IL-2 
indicator T cell line, in a proliferation assay to assess SJL-PLP cell growth. Based on the SJL-
PLP proliferation assay, IFN-β alone did not have a distinguishable effect on IL-2 production by 
the human T cells compared to the control group (Figure 3). TGF-β enabled robust IL-2 
production by the human T cells, as measured by SJL-PLP expansion. However, in human T cell 
cultures that were initially activated with TGF-β versus TGF-β + IFN-β, the reactivation showed 
that inclusion of IFN-β in the original culture resulted in significantly less IL-2 production in the 
recall assay. The results suggest that IFN-β dampens human T cell responsiveness to 
reactivation, inhibiting IL-2 production and thus preventing T cell expansion. 
 
Figure 3. SJL-PLP proliferation assay.  On day 0, human T cells were activated with either 10 
nM IFN-β, TGF-β, IFN-β + TGF- β, no cytokine, or no activation.  In a 96 well plate, triplicates 
of each group contained a 1:1 ratio of irradiated RS4 (11) cells and human T cells (90% CD8+ T 
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Activation w/o cytokine
No activation
On day 1, T cells were removed from activation cultures and passaged every three days in new 
media and 1% IL-2 (without TGF-β and/ or IFN-β). On day 7, each group of human T cells were 
reactivated in the presence of a 1:1 ratio of irradiated RS4 (11) cells to T cells and 2.5 μg/mL 
Con-A.  As a measure of T cell responsiveness, IL-2 production was measured in an IL-2 
indicator cell proliferation assay.  On day 8, supernatants were collected and were used to culture 
10,000 IL-2 indicator cells per well at designated titrations (x-axis).  On day 10, the plate was 
pulsed with 1 μCi/well [3H]thymidine.  On day 11, the plate was harvested and counts per minute 












The pIRES2-AcGFP1 IFN-β-8his plasmid provides a reliable method for mass producing 
and purifying IFN-β for future experiments in the laboratory. In particular, IFN-β produced by 
this expression system can be used to activate human T cells to observe whether IFN-β results in 
the differentiation of Foxp3+ Tregs. As observed in the study, IFN-β induced T cell anergy in a 
primary activation of PBMCs and inhibited IL-2 production by T cells after an initial activation 
with IFN-β. These findings are the foundation of creating a consistent method of producing a 
pure Treg cell line required for future research and treatments. One of the newer treatments for 
autoimmune disorders being investigated is adoptive cellular immunotherapy (10). Adoptive 
immunotherapy involves the reintroduction of Foxp3+ Tregs into an individual in order to 
suppress the autoimmune disease (10). This therapy, unlike previous treatments using only IFN-
β, aims to be a curative treatment for autoimmune diseases. Use of Tregs has already been 
performed in clinical trials involving kidney transplant patients. Results from clinical trials 
suggested that laboratory-expanded Tregs increased circulating Treg populations in patients and 
prevented transplant rejection for two years (11). In order for cellular adoptive immunotherapy to 
be used in MS clinical trials, methods for robust pure Treg cell expansion need to be devised. 
The first step for producing a pure Treg cell line would be testing human T cell activation 
in the presence of human IFN-β, anti-human CD25 monoclonal antibodies, and Rapamycin. As 
previously stated, IFN-β has been found to cause the differentiation of Foxp3+ Treg cells in mice, 
thus promoting Treg cell expansion (9). Anti-human CD25 monoclonal antibodies would be used 
due to the disparity of CD25 expression on Tregs compared to effector T cells (10). Effector T 
cell populations have decreased amounts of CD25 expression, allowing for complete inhibition 
of IL-2 uptake by CD25 in effector T cells while only partially inhibiting IL-2 uptake in Tregs 
(10). Due to the inhibition of CD25, effector T cell proliferation would be inhibited. This can be 
further induced by use of Rapamycin, a drug capable of blocking PI3K-mediated signaling in 
effector T cells (12). Effector T cells use a PI3K-mediated and a JAK/STAT-IL-2 signaling 
pathway for cell growth, whereas Tregs only require the JAK/STAT-IL-2 signaling pathway 
(12). Therefore, by inhibiting only the PI3K-mediated signaling pathway, pure Treg expansion 
may be able to occur (12). A pure Treg cell line will be beneficial for future research regarding 
adoptive immunotherapy, MS treatment, including the potential effect IFN-β has on the 
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